Jiajia Zhao is a clinical pharmacologist for several oncology drugs including Mab, BsAb, ADC and in-vivo CAR-T. She led Clin Pharm strategy, dossier, execution and health authority interactions for PACIFIC4/5/9, POSEIDON, AEGEAN, ADRIATIC, and KOSELUGO BLA/NDA with 4 approvals achieved. In early development, she led ADC combination neutropenia risk modelling for safe dose prediction and co-led EGFR L858R Clin Pharm plan. She’d like to improve her knowledge and skills in M&S.